Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection
Antibiotics · 16.03.2023 · 12 (3) · 593
DOI: 10.3390/antibiotics12030593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 16.03.2023. Verfasst von Isaac Martin und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Building, London SW3 6LY, UK. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Trust, UK, Strategic Research Centre for Pseudomonas.
Abstract (Originalsprache)
Bacteriophages (phages) are antimicrobials with resurgent interest that are being investigated for the treatment of antibiotic refractory infection, including for Pseudomonas aeruginosa (Pa) lung infection in cystic fibrosis (CF). In vitro work supports the use of this therapy in planktonic and biofilm culture models; however, consistent data are lacking for efficacy across different clinical Pa strains, culture models, and in combination with antibiotics in clinical use. We first examined the efficacy of a 4-phage cocktail as an adjunct to our CF centre’s first-line systemic combination antibiotic therapy (ceftazidime + tobramycin) for 16 different clinical Pa strains and then determined subinhibitory interactions for a subset of these strains with each antibiotic in planktonic and biofilm culture. When a 4-phage cocktail (4 × 108 PFU/mL) was added to a ceftazidime-tobramycin combination (ceftazidime 16 mg/mL + tobramycin 8 mg/mL), we observed a 1.7-fold and 1.3-fold reduction in biofilm biomass and cell viability, respectively. The four most antibiotic resistant strains in biofilm were very susceptible to phage treatment. When subinhibitory concentrations of antibiotics and phages were investigated, we observed additivity/synergy as well as antagonism/inhibition of effect that varied across the clinical strains and culture model. In general, more additivity was seen with the phage-ceftazidime combination than with phage-tobramycin, particularly in biofilm culture, where no instances of additivity were seen when phages were combined with tobramycin. The fact that different bacterial strains were susceptible to phage treatment when compared to standard antibiotics is promising and these results may be relevant to ongoing clinical trials exploring the use of phages, in particular in the selection of subjects for clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Heart and Lung Institute, Imperial College London, Emmanuel Kaye Building, London SW3 6LY, UK.
- Royal Brompton Hospital, Part of Guy's and St. Thomas' Trust, Sydney St., London SW3 6NP, UK.
- Department of Paediatrics and Translational Medicine, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
- AmpliPhi Biosciences, Brookvale, NSW 2100, Australia.
ORCID-Profile: Sandra Morales
Förderung
- Cystic Fibrosis Trust, UK
- Strategic Research Centre for Pseudomonas
Zitieren
APA
Martin, I., Morales, S., Alton, E. W. F. W., & Davies, J. C. (2023). Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection. Antibiotics, 12(3), 593. https://doi.org/10.3390/antibiotics12030593
Vancouver
Martin I, Morales S, Alton EWFW, Davies JC. Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection. Antibiotics. 2023;12(3):593. doi:10.3390/antibiotics12030593
BibTeX
@article{Martin2023,
author = {Martin, Isaac and Morales, Sandra and Alton, Eric W F W and Davies, Jane C},
title = {Lytic Bacteriophage Is a Promising Adjunct to Common Antibiotics across Cystic Fibrosis Clinical Strains and Culture Models of Pseudomonas aeruginosa Infection},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {3},
pages = {593},
doi = {10.3390/antibiotics12030593}
}
EUVIMED